ProfileGDS5678 / 1417765_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 62% 75% 88% 79% 65% 75% 89% 91% 90% 64% 82% 77% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.805874
GSM967853U87-EV human glioblastoma xenograft - Control 23.6905162
GSM967854U87-EV human glioblastoma xenograft - Control 34.9706475
GSM967855U87-EV human glioblastoma xenograft - Control 47.0343888
GSM967856U87-EV human glioblastoma xenograft - Control 55.540379
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9276465
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8831875
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8993289
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2789691
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1713790
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.857864
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0587782
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2516577
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7433274